Reducing hepatitis C diagnostic disparities with a fully automated deep learning–enabled microfluidic system for HCV antigen detection
Open Access
- 21 March 2025
- journal article
- engineering
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (12) , eadt3803
Abstract
Viral hepatitis remains a major global health issue, with chronic hepatitis B (HBV) and hepatitis C (HCV) causing approximately 1 million deaths annually, primarily due to liver cancer and cirrhosis. More than 1.5 million people contract HCV each year, disproportionately affecting vulnerable populations, including American Indians and Alaska Natives (AI/AN). While direct-acting antivirals (DAAs) are highly effective, timely and accurate HCV diagnosis remains a challenge, particularly in resource-limited settings. The current two-step HCV testing process is costly and time-intensive, often leading to patient loss before treatment. Point-of-care (POC) HCV antigen (Ag) testing offers a promising alternative, but no FDA-approved test meets the required sensitivity and specificity. To address this, we developed a fully automated, smartphone-based POC HCV Ag assay using platinum nanoparticles, deep learning image processing, and microfluidics. With an overall accuracy of 94.59%, this cost-effective, portable device has the potential to reduce HCV-related health disparities, particularly among AI/AN populations, improving accessibility and equity in care.Keywords
This publication has 68 references indexed in Scilit:
- Total HCV core antigen assayJournal of Virological Methods, 2004
- Variable Ratio of Hepatitis C Virus RNA to Viral Core Antigen in Patient SeraJournal of Clinical Microbiology, 2004
- Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination TherapyJournal of Clinical Microbiology, 2003
- Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatmentJournal of Viral Hepatitis, 2003
- Total HCV core antigen assay: A new marker of hepatitis C viremia for monitoring the progress of therapyJournal of Medical Virology, 2003
- Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replicationHepatology, 2002
- Hepatitis C virus infection in renal failure patients in the absence of anti‐hepatitis C virus antibodiesJournal of Viral Hepatitis, 2002
- Point-of-Care Testing: Impact on Medical OutcomesClinics In Laboratory Medicine, 2001
- Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNAHepatology, 2000
- Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core AntigenJournal of Clinical Microbiology, 1999